You're seeing lots of cardiovascular news this week because the annual meeting of the American College of Cardiology is going on in New Orleans.
I applaud the health news coverage of the Wall Street Journal, but even their coverage shows a bias toward the positive and against negative findings.
In today's WSJ, the front page of the "Marketplace" section, page B1, has a story on the "blockbuster drug plavix" and a pack of new rivals on the horizon.
But negative findings on two other drug studies are relegated to pages B6 and B7, deep in the paper and deeper in that section.
Stories headlined "Crestor Fails to Clear A Bar in Arterial Study" and "Two Heart-Failure Drugs Fail to Reduce Death, Admissions" were important, but got neither the quality nor quantity of space given to the generally positive Plavix (and rivals) story.
American consumers need to be reminded that not all drugs are blockbusters, and that hopes at the beginning of trials are often dashed at the end. Page 1 placement would drive that point home.
(But at least the WSJ reports on the negative findings somewhere - don't get me wrong.)